Flagship Pioneering, LLC — SEC Form 4 filings
SEC reporting owner CIK 1400240. 4 Form 4 filings on record with FilingPulse; latest filed 2026-03-02.
Transaction summary — filings shown
Covers all 4 filings on record, filed 2024-02-14 to 2026-03-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 1 filing — 4,687,500 shares, $75,000,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 22.
- Largest priced transaction: purchase of 1,562,500 shares @ $16.00 ($25,000,000) in Generate Biomedicines, Inc., filed 2026-03-02.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Generate Biomedicines, Inc. (GENB) | 10% owner | 1 | 3 legs · 4,687,500 sh · $75,000,000 | — | 16 |
| Foghorn Therapeutics Inc. (FHTX) | Director, 10% owner | 2 | — | — | 5 |
| Sana Biotechnology, Inc. (SANA) | 10% owner | 1 | — | — | 1 |
Form 4 filings — Flagship Pioneering, LLC
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-02 | 4 | Generate Biomedicines, Inc. (GENB) jointly with AFEYAN NOUBAR, Flagship VentureLabs VI Manager LLC, Flagship Pioneering Fund VI General Partner LLC, Flagship Pioneering Fund VII General Partner LLC, Nutritional Health LTP Fund General Partner LLC, Flagship Pioneering Special Opportunities Fund II General Partner LLC, FPN General Partner LLC | Conversion (C): 12,723,940 · Conversion (C): 13,702,224 · Conversion (C): 987,491 · Conversion (C): 2,777,752 · Conversion (C): 2,777,752 · Purchase (P): 1,562,500 @ $16 · +13 more | EDGAR |
| 2026-01-15 | 4 | Foghorn Therapeutics Inc. (FHTX) jointly with Flagship Pioneering Fund VII General Partner LLC, Flagship Pioneering Fund VII, L.P., Flagship Pioneering Special Opportunities Fund II General Partner LLC, Flagship Pioneering Special Opportunities Fund II, L.P., Flagship Ventures Fund V General Partner LLC, Flagship Ventures Fund V, L.P., Flagship Ventures Opportunities Fund I General Partner LLC, Flagship Ventures Opportunities Fund I, L.P., AFEYAN NOUBAR | Grant/award (A): 2,235,468 (derivative) @ $6.71 · Grant/award (A): 1,117,734 (derivative) · Grant/award (A): 1,117,734 (derivative) | EDGAR |
| 2024-05-24 | 4 | Foghorn Therapeutics Inc. (FHTX) jointly with Flagship Pioneering Special Opportunities Fund II General Partner LLC, Flagship Pioneering Special Opportunities Fund II, L.P., AFEYAN NOUBAR | Purchase (P): 1,814,914 (derivative) @ $5.51 · Purchase (P): 1,814,915 (derivative) @ $5.51 | EDGAR |
| 2024-02-14 | 4 | Sana Biotechnology, Inc. (SANA) jointly with AFEYAN NOUBAR | Purchase (P): 2,727,272 (derivative) @ $5.50 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1400240 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →